Ectopic Cushing's Syndrome Due to Concurrent Corticotropin-Releasing Hormone (CRH) and Adrenocorticotropic Hormone (ACTH) Secreted by Malignant Gastrinoma

 

 Buy Article Permissions and Reprints

Abstract

Ectopic Cushing's syndrome due to various malignancies is not uncommon. However, a few cases of ectopic Cushing's syndrome caused by corticotropin-releasing hormone (CRH), or CRH with adrenocorticotropic hormone (ACTH) have been reported. A 28-year-old woman presented with acute upper gastrointestinal bleeding caused by an active ulcer, located atypically in the 2^nd portion of duodenum. Further work-up revealed high gastrin levels and abdominal computed tomography (CT) scans showed a large pancreatic head mass with multiple liver metastases. The serum cortisol and ACTH levels were checked due to hypokalemia with metabolic alkalosis and recent amenorrhea. Cortisol and ACTH were both highly elevated with pituitary hyperplasia and elevated CRH. The existence of ectopic ACTH and CRH in the liver biopsy was also demonstrated immunohistochemically. Since an operation was not feasible, chemotherapy was conducted using paclitaxel and etoposide. These two drugs were chosen according to the in vitro chemotherapy response assay to maximize the treatment. This report demonstrates concurrent ACTH- and CRH-related ectopic Cushing's syndrome caused by malignant gastrinoma with multiple liver metastases that was treated with marginal success using a multidisciplinary medical approach.

References

• 1 de Herder WW, Krenning EP, van Eijck CHJ, Lamberts SWJ. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.  Endocrine-Related Cancer. 2004;  11 19-34
  PubMedGoogle Scholar
• 2 Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.  Annals of Oncology. 1997;  8 1041-1044
  CrossrefPubMedGoogle Scholar
• 3 Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.  Recent Results in Cancer Research. 1996;  142 193-207
  PubMedGoogle Scholar
• 4 Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group.  J Clin Oncol. 2003;  21 2689-2696
  PubMedGoogle Scholar
• 5 Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent CushingÂ’s syndrome: comparison of the features in ectopic and pituitary ACTH production.  Clinical endocrinology. 1986;  24 699-713
  CrossrefPubMedGoogle Scholar
• 6 Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphatebased luminescence measurements.  Methods Mol Med. 2005;  110 101-120
  PubMedGoogle Scholar
• 7 Lamberts SW, de Herder WW, Krenning EP, Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of CushingÂ’s syndrome.  J Clin Endocrinol Metab. 1994;  78 17-19
  CrossrefPubMedGoogle Scholar
• 8 Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide.  N Engl J Med. 1996;  334 246-254
  CrossrefPubMedGoogle Scholar
• 9 Maton PN, Gardner JD, Jensen RT. CushingÂ’s syndrome in patients with the Zollinger- Ellison syndrome.  N Engl J Med. 1986;  315 1-5
  PubMedGoogle Scholar
• 10 Mitry E, Baudin D, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin.  British Journal of Cancer. 1999;  81 1351-1355
  CrossrefPubMedGoogle Scholar
• 11 Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini PL, Roy PK, Gibril F, Jensen RT. Surgery to cure the Zollinger-Ellison syndrome.  N Engl J Med. 1999;  341 635-644
  CrossrefPubMedGoogle Scholar
• 12 Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review.  Digestion. 2000;  62 ((Suppl 1)) 92-97
  CrossrefPubMedGoogle Scholar
• 13 Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors.  Annals of Oncology. 2001;  12 S111-S114
  CrossrefPubMedGoogle Scholar
• 14 O’Brien T, Young Jr WF, Davila DG, Scheithauer BW, Kovacs K, Horvath E, Vale W, Heerden JA. CushingÂ’s syndrome associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and vasopressin by a phaeochromocytoma.  Clinical endocrinology. 1992;  37 460-467
  PubMedGoogle Scholar
• 15 Rickman T, Garmany R, Doherty T, Benson D, Okusa MD. Hypokalemia, metabolic alkalosis, and hypertension : CushingÂ’s syndrome in a patient with metastatic prostate adenocarcinoma.  American journal of kidney diseases. 2001;  347 838-846
  PubMedGoogle Scholar
• 16 Saijo F, Naito H, Funayama Y, Fukushima K, Shibata C, Hashimoto A, Kitayama T, Nagao M, Matsuno S, Sasaki I. Octreotide in control of multiple liver metastases from gastrinoma.  J Gastroenterol. 2003;  38 905-908
  CrossrefPubMedGoogle Scholar
• 17 Schteingart DE, Lloyd RV, Akil H, Chandler WF, Ibarra-Perez G, Rosen SG, Ogletree R. CushingÂ’s syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion.  J Clin Endocrinol Metab. 1986;  63 770-775
  CrossrefPubMedGoogle Scholar
• 18 Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, Catargi B, Roger P, Laurent F. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome.  J Clin Endocrinol Metab. 1999;  84 1193-1202
  CrossrefPubMedGoogle Scholar
• 19 Tsuchihashi T, Yamaguchi K, Abe K, Yanaihara N, Saito S. Production of immunoreactive corticotropin-releasing hormone in various neuroendocrine tumors.  Jpn J Clin Oncol. 1992;  22 232-237
  PubMedGoogle Scholar
• 20 Vrezas I, Willenberg HS, Mansmann G, Hiroi N, Fritzen R, Bornstein SR. Ectopic adrenocorticotropin (ACTH) and corticotropin-releasing hormone (CRH) production in the adrenal gland: basic and clinical aspects.  Microscopy research and technique. 2003;  61 308-314
  PubMedGoogle Scholar
• 21 Wajchenberg BL, Mendonca BB, Liberman B, Pereira MA, Carneiro PC, Wakamatsu A, Kirschner MA. Ectopic adrenocorticotropic hormone syndrome.  Endocrine reviews. 1994;  15 752-787
  CrossrefPubMedGoogle Scholar
• 22 Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic CushingÂ’s syndrome secondary to ectopic adrenocorticotropin production.  J Clin Oncol. 1995;  13 157-164
  PubMedGoogle Scholar
• 23 Young J, Deneux C, Grino M, Oliver C, Chanson P, Schaioson G. Pitfall of petrosal sinus sampling in a Cushing's syndrome secondary to ectopic adrenocorticotropin-corticotropin releasing hormone (ACTH-CRH) secretion.  J Clin Endocrinol Metab. 2005;  83 305-308
  PubMedGoogle Scholar
• 24 Yu F, Venzon DJ, Serrano J, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.  J Clin Oncol. 1999;  17 615-630
  PubMedGoogle Scholar
• 25 Zarate A, Kovacs K, Flores M, Moran C, Felix I. ACTH and CRF-producing bronchial carcinoid associated with CushingÂ’s syndrome.  Clinical endocrinology. 1986;  24 523-529
  PubMedGoogle Scholar

Correspondence

Y. Rhee

Division of Endocrinology

Department of Internal Medicine

Yonsei University College of Medicine

Shinchon-Dong 134

Seodaemun-Ku

Seoul

120-752

Korea

Phone: +82/2222/81 97 3

Fax: +82/2392/55 48

Email: yumie@yumc.yonsei.ac.kr